MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8423
-0.0237
-2.74%
Opening 09:30 01/27 EST
OPEN
0.8423
PREV CLOSE
0.8660
HIGH
0.8423
LOW
0.8423
VOLUME
1.31K
TURNOVER
--
52 WEEK HIGH
4.360
52 WEEK LOW
0.7888
MARKET CAP
11.40M
P/E (TTM)
-0.6914
1D
5D
1M
3M
1Y
5Y
18 Stocks Moving in Friday's Pre-Market Session
Check out these penny stocks insiders are buying
Benzinga · 6d ago
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military.
Benzinga · 01/12 17:00
Immuron, Immix lead healthcare gainers; Philips, Prothena among losers
Gainers: Immuron (NASDAQ:IMRN) +43%. Immix Biopharma (NASDAQ:IMMX) +28%. Sonendo (NYSE:SONX) +16%. IRIDEX (NASDAQ:IRIX) +13%. NEXGEL (NXGL) +10%. Losers: Koninklijke Philips (NYSE:PHG) -15%. Prothena (NASDAQ:PRTA) -13%. Biogen (NASDAQ:BIIB) -10%. Phio Phar...
Seekingalpha · 01/12 15:02
15 Stocks Moving in Wednesday's Pre-Market Session
Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share.
Benzinga · 01/12 11:44
French Regulatory Authority Gives Green Signal To Phio Pharma's Melanoma Trial
The French National Agency for the Safety of Medicines and Health Products has signed off Phio Pharmaceuticals Corp's (NASDAQ: PHIO) clinical trial with
Benzinga · 01/11 17:08
Phio Pharma gets French regulatory nod to start clinical trial for lead asset
Phio Pharmaceuticals (NASDAQ:PHIO) is trading ~11.6% higher in the pre-market after announcing it obtained regulatory clearance from Frech authorities to start a clinical trial for its lead candidate PH-762 for melanoma. With
Seekingalpha · 01/11 13:05
BRIEF-Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial For PH-762 To Treat Melanoma
reuters.com · 01/11 12:47
Phio Pharmaceuticals Announces French Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma
 Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
Benzinga · 01/11 12:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PHIO. Analyze the recent business situations of Phio Pharmaceuticals Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PHIO stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
High6.00
Average6.00
Low6.00
Current 0.8423
EPS
Actual
Estimate
-0.34-0.25-0.17-0.08
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 22
Institutional Holdings: 1.50M
% Owned: 11.10%
Shares Outstanding: 13.53M
TypeInstitutionsShares
Increased
7
259.64K
New
3
31.56K
Decreased
5
31.88K
Sold Out
4
60.74K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.92%
Pharmaceuticals & Medical Research
+1.16%
Key Executives
Non-Executive Chairman/Independent Director
Robert Bitterman
President/Chief Executive Officer
Gerrit Dispersyn
Independent Director
Geert Cauwenbergh
Independent Director
H. Paul Dorman
Independent Director
Robert Ferrara
Independent Director
Jonathan Freeman
Independent Director
Curtis Lockshin
No Data
About PHIO
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.